IPM Take
Duchenne policy often talks about function after function is already disappearing.
That is why muscle-level evidence matters. Imaging data can show whether treatment is changing the tissue before the loss becomes visible in daily life. But MRI should not become another surrogate that outruns what families need most: walking, breathing, independence and fewer irreversible losses.
The new givinostat data are a useful signal. They should sharpen the evidence conversation, not replace it.
Executive Summary
Italfarmaco presented new clinical data on givinostat in Duchenne muscular dystrophy at the 2026 International Congress on Neuromuscular Diseases.
The company reported MRI findings from the Phase III EPIDYS study showing differences favouring givinostat in contractile cross-sectional area and muscle fat fraction across lower-limb muscles. It also reported long-term open-label extension findings in 225 participants, including a median age at persistent loss of ambulation of 17.3 years, compared with published natural-history estimates of 11.0 to 13.4 years.
The company also reported that long-term safety data, including exposure beyond 10 years in some participants, remained generally consistent with the known safety profile and did not reveal new safety signals.
These findings are conference-presented and company-reported. The long-term ambulation comparison uses natural-history benchmarks, not a randomised concurrent comparator. Givinostat is already approved in several regions, but access, eligibility and reimbursement vary by jurisdiction.
Why it matters
- Patients / advocates: The outcome that matters is not a better scan by itself. It is whether boys and young men keep function for longer.
- Clinicians: MRI can help connect tissue preservation to clinical change, but interpretation must remain anchored to functional outcomes and safety.
- Researchers / academia: The data support further use of imaging as a disease-progression measure, while highlighting the limits of historical comparisons.
- Regulators: Post-approval evidence needs to clarify durability, real-world effectiveness and which patients benefit most.
Duchenne is a disease of visible loss, but the damage starts before families can see it clearly.
Muscle tissue changes. Fat replaces function. A boy who was slower becomes less able to climb, run or rise from the floor. Later, the question becomes whether ambulation can be preserved, and for how long.
That is why the givinostat MRI data are more than a technical add-on. Imaging can help show whether the disease process is being altered at the tissue level, not only reflected later in a functional test. The EPIDYS findings presented at ICNMD suggest differences favouring givinostat in muscle preservation measures, alongside longer-term extension data that point toward later loss of ambulation compared with natural-history expectations.
But this is where Duchenne evidence has to stay honest.
Families have lived through enough regulatory and access debates built around endpoints that were meaningful to scientists but harder to translate into daily life. A preserved muscle area matters because it may help preserve function. It does not matter enough by itself.
The long-term data are also not a clean randomised comparison. Open-label extension studies and natural-history benchmarks can be valuable, especially in rare diseases where long-term placebo control is difficult. But they come with uncertainty, and that uncertainty should not be edited out because the story is hopeful.
The stronger conclusion is better.
Givinostat is building a broader evidence package that connects imaging, function and longer-term follow-up. That is exactly what Duchenne needs. Not isolated claims. Not single endpoints doing all the work. A layered case showing whether treatment changes the body in ways that families can feel in movement, independence and time.
